BR0308391A - Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores - Google Patents

Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores

Info

Publication number
BR0308391A
BR0308391A BR0308391-8A BR0308391A BR0308391A BR 0308391 A BR0308391 A BR 0308391A BR 0308391 A BR0308391 A BR 0308391A BR 0308391 A BR0308391 A BR 0308391A
Authority
BR
Brazil
Prior art keywords
pyridine derivatives
pyrazolo
crf
neurotransmitter modulators
receptors
Prior art date
Application number
BR0308391-8A
Other languages
English (en)
Inventor
Jian-Min Fu
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BR0308391A publication Critical patent/BR0308391A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"DERIVADOS DE PIRAZOLO(1,5-a)PIRIDINA COMO MODULADORES NEUROTRANSMISSORES". A presente invenção refere-se a novos derivados de pirazolo[1,5-a]piridina de fórmula geral (I) que se ligam com afinidade elevada aos receptores do CRF~ 1~, incluindo receptores do CRF~ 1~ humano. Esta invenção também refere-se aos métodos de uso dos compostos da invenção para tratar um distúrbio ou condição, cujo tratamento pode ser efetuado ou facilitado por antagonizar um receptor do CRF, tal como distúrbios ou doenças do CNS, particularmente distúrbios da ansiedade, e depressão e distúrbios relacionados ao estresse.
BR0308391-8A 2002-03-13 2003-03-11 Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores BR0308391A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36376602P 2002-03-13 2002-03-13
US38057602P 2002-05-14 2002-05-14
US40354702P 2002-08-14 2002-08-14
PCT/US2003/007533 WO2003078435A1 (en) 2002-03-13 2003-03-11 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators

Publications (1)

Publication Number Publication Date
BR0308391A true BR0308391A (pt) 2005-01-11

Family

ID=28046498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308391-8A BR0308391A (pt) 2002-03-13 2003-03-11 Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores

Country Status (8)

Country Link
US (1) US7151109B2 (pt)
EP (1) EP1485384A1 (pt)
JP (1) JP2005526090A (pt)
AU (1) AU2003220190A1 (pt)
BR (1) BR0308391A (pt)
CA (1) CA2478715A1 (pt)
MX (1) MXPA04008790A (pt)
WO (1) WO2003078435A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
PL214231B1 (pl) 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7323569B2 (en) * 2002-10-22 2008-01-29 Eisai R&D Management Co., Ltd. 7-phenylpyrazolopyridine compounds
US7402672B2 (en) * 2003-12-11 2008-07-22 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
WO2005100354A1 (ja) 2004-04-12 2005-10-27 Eisai R & D Management Co., Ltd. ピラゾール縮合環誘導体の製造方法
EP1791537B1 (en) * 2004-08-19 2009-10-14 Aventis Pharmaceuticals, Inc. 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
MY150731A (en) 2006-11-27 2014-02-28 Lundbeck & Co As H Heteroaryl amide derivatives
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
EP2320737B1 (en) * 2008-08-05 2013-07-17 Merck Sharp & Dohme Corp. Pyrazolo-[1,5-a]-pyridines as mark inhibitors
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
US8946237B2 (en) 2010-01-14 2015-02-03 Merck Sharp & Dohme Corp. Pyrazolo[1,5-A]pyrimidines as mark inhibitors
EP2585467B1 (en) 2010-06-24 2016-03-02 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
NZ701647A (en) 2012-04-17 2016-05-27 Gilead Sciences Inc Compounds and methods for antiviral treatment
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197285A (ja) * 1984-10-17 1986-05-15 Taiho Yakuhin Kogyo Kk ピラゾロピリジン化合物
DE3942355A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel
HRP980375A2 (en) 1997-07-03 1999-04-30 Argyrios Georgios Arvanitis Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
JPH11265080A (ja) * 1998-03-18 1999-09-28 Mitsubishi Paper Mills Ltd 電子写真感光体
JPH11265079A (ja) * 1998-03-18 1999-09-28 Mitsubishi Paper Mills Ltd 電子写真感光体
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
ATE260918T1 (de) * 2000-05-18 2004-03-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
FR2822689B1 (fr) * 2001-03-27 2005-01-28 Oreal Composition pour la teinture d'oxydation contenant au moins une base d'oxydation 3-amino pyrazolo-[1,5-a] pyridine et au moins un coupleur du type 2-amino 3-hydroxy pyridine
FR2822692B1 (fr) * 2001-03-27 2005-01-28 Oreal Composition pour la teinture d'oxydation contenant au moins une base d'oxydation 3-amino pyrazolo-[1,5-a]-pyridine et au moins un coupleur aminophenol particulier
FR2822691B1 (fr) * 2001-03-27 2005-02-25 Oreal Composition pour la teinture d'oxydation contenant au moins une base d'oxydation 3-amino pyrazolo-[1,5-a]-pyridine et au moins un coupleur pyridinique particulier
FR2822690B1 (fr) * 2001-03-27 2003-05-09 Oreal Composition pour la teinture d'oxydation contenant au moins une base d'oxydation 3-amino pyrazolo[1,5-a]- pyridine et au moins un coupleur pyrazolotriazole particulier
PL214231B1 (pl) * 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie

Also Published As

Publication number Publication date
AU2003220190A1 (en) 2003-09-29
MXPA04008790A (es) 2004-11-26
JP2005526090A (ja) 2005-09-02
US20040002511A1 (en) 2004-01-01
US7151109B2 (en) 2006-12-19
EP1485384A1 (en) 2004-12-15
CA2478715A1 (en) 2003-09-25
WO2003078435A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
BR0308391A (pt) Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores
CR9389A (es) Compuestos de imidazopiridazina
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
MXPA03005493A (es) Derivados de bencimidazol y piridilmidazol como ligandos para receptores gaba.
WO2001034603A3 (en) Bicyclic and tricyclic heteroaromatic compounds
WO2009062676A3 (en) Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2007016155A3 (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
WO2008057575A3 (en) Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
BRPI0409649A (pt) pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
BRPI0410127A (pt) derivados de pirimidina substituìdos
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
BRPI0512540A (pt) composto de fórmula; método para o tratamento de um distúrbio do sistema nervoso central; composição farmacêutica; método para a determinação do metabolismo de um derivado de (1-arilsulfonil-1h-indol-3-il)etilamina; e uso do composto
BR0309551A (pt) Derivados substituìdos de pirazina
WO2004099213A3 (en) Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
BR0307584A (pt) Pirimidinonas e pirimidinationas substituìdas
Walsh et al. Comparative inhibition by substrate analogues 3-methoxy-and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase.
HRP20060008A2 (en) 7-substituted 3-nitro-pyrazolo[1,5-a] pyrimidines
BRPI0410191A (pt) pirazinonas como antogonistas de receptor de crf1, composição farmacêutica, método de inibir ligação do crf ao receptor crf1, e para triagem de ligandos de receptores de crf
BR0315845A (pt) Compostos de pirazina como moduladores de crf
TNSN05324A1 (en) 7-substituted 3-nitro-pyrazolo `1,5-a! pyrimidines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.